Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythropoietin.

J L Spivak1

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Blood Reviews
|June 1, 1989
PubMed
Summary
This summary is machine-generated.

Recombinant erythropoietin (EPO) therapy effectively treats anemia in patients with end-stage renal disease. This breakthrough alleviates transfusion needs for anemic patients undergoing dialysis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The third International Congress on Myeloproliferative and Myelodysplastic Syndromes.

Leukemia research·2006
Same author

The second international congress on myeloproliferative and myelodysplastic syndromes.

Leukemia research·2004
Same author

Erythropoietin use and abuse: When physiology and pharmacology collide.

Advances in experimental medicine and biology·2002
Same author

A mail survey of United States hematologists and oncologists: a comparison of business reply versus stamped return envelopes.

Journal of clinical epidemiology·2001
Same author

Current thinking and treatment practices in anaemia--an interactive poll.

Medical oncology (Northwood, London, England)·2001
Same author

A novel thrombopoietin signaling defect in polycythemia vera platelets.

Stem cells (Dayton, Ohio)·2000
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Nephrology

Background:

  • Erythropoietin (EPO) is a kidney-produced glycoprotein hormone regulating red blood cell production.
  • Inadequate EPO production causes severe anemia, particularly in end-stage renal disease (ESRD).
  • EPO's critical physiological role is underscored by its consistent presence in plasma.

Purpose of the Study:

  • To investigate the efficacy of recombinant erythropoietin (rEPO) in treating anemia associated with ESRD.
  • To assess the impact of rEPO on transfusion requirements in anemic ESRD patients.

Main Methods:

  • Molecular cloning, sequencing, and expression of the human EPO gene in mammalian cells.
  • Clinical trials involving patients with severe ESRD and anemia.

Related Experiment Videos

Main Results:

  • Recombinant EPO was successfully produced in a biologically active form.
  • Clinical trials demonstrated that rEPO effectively corrects anemia in ESRD patients.
  • rEPO therapy significantly reduced the need for blood transfusions in treated patients.

Conclusions:

  • Recombinant DNA technology has enabled the production of therapeutic EPO.
  • rEPO is a viable and effective treatment for anemia in end-stage renal disease.
  • rEPO therapy offers a significant clinical benefit by reducing transfusion dependency.